Apr 29, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks Under Review: Ariad Pharmaceuticals Inc (NASDAQ:ARIA), Intrexon Corp (NYSE:XON), Inovio Pharmaceuticals Inc (NASDAQ:INO)

Stocks Under Review: Ariad Pharmaceuticals Inc (NASDAQ:ARIA), Intrexon Corp (NYSE:XON), Inovio Pharmaceuticals Inc (NASDAQ:INO)

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) plunged -0.69% and ended at $7.17. The total traded volume was 2.37 million shares and market capitalization arrived at $1.36 billion. The stock has a 52-week high price of $10.07 and its 52-week low was recorded at $4.37, while during last trade its minimum price was $7.13 and it gained the highest price of $7.44.

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) on April 26, 2016 announced that it will report its first quarter 2016 financial results on Tuesday, May 10, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.

Intrexon Corp (NYSE:XON) reported the decrease of -1.43% to close at $26.85 with the overall traded volume of 2.20 million shares. Its market capitalization on last close reached to $3.17 billion. The company has the total of 116.78 million outstanding shares. Its intraday-low price was $26.55 and its hit its day’s highest price at $27.98.

Intrexon Corp (NYSE:XON) on April 28, 2016 announced that it will release first quarter 2016 financial results after the market closes on Tuesday, May 10th, 2016.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update.

Intrexon Corporation (XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  Intrexon’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.

Inovio Pharmaceuticals Inc (NASDAQ:INO) moved up +2.29% to settle at $11.18. Its total traded volume during last trading session was 2.16 million shares. The overall market worth of this company is about $842.94 million. The 52 week range of the stock remained $4.50 – $11.69, while its day’s lowest price was $10.90 and its hit its day’s highest price at $11.69. The beta of this stock currently stands at 2.65.

Inovio Pharmaceuticals Inc (NASDAQ:INO) on April 27, 2016 announced that its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments. The study will enroll patients who are in the early stages of chronic HCV infection to determine the therapy’s ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability. In this dose-escalation study INO-8000 will be combined with increasing doses of DNA-based IL-12 (INO-9012), an immune activator, which in previous studies has been shown to increase the therapeutic immune response to DNA immunotherapies.

The study is funded by the National Cancer Institute’s Division of Cancer Prevention and will be conducted at the Mayo Clinic and other U.S. sites.

Among those initially infected with HCV, 75 to 85 percent will go on to develop chronic illness. More than 170 million people around the world are chronically infected with HCV. According to the U.S. Centers for Disease Control (CDC) an estimated 3.5 million people in the US are chronically infected with HCV, with about 20,000 new cases of chronic HCV reported in the US in the last year. About 15,000 people in the US die each year of HCV-related causes.

Inovio’s SynCon® DNA immunotherapy, INO-8000, is encoded for the antigens NS3/4A, NS4B, and NS5A of HCV genotypes 1a and 1b, the most difficult-to-treat genotypes. The product is designed to induce robust T cells to eliminate cells displaying these antigens and has been shown in published preclinical studies to generate powerful HCV-specific T cell responses throughout the body and in the liver.

 

Comments are closed.